Notice of insurance coverage of the disease diagnosis program “EGFR Liquid” Gene Analysis Software in Japan

DNA Chip Research Inc. (President: Ryo Matoba) is pleased to announce that May 21, 2021 onward, a function of the “EGFR Liquid” Gene Analysis Software (test using unfixed tissue sample) will be covered by public insurance of Japan. The “EGFR Liquid” Gene Analysis Software is a disease diagnosis program for detecting mutations in the gene encoding epidermal growth factor receptor (EGFR) using DNA extracted from cancer tissues or plasma samples and determining drug efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients.
>Read more